Health ❯ Healthcare ❯ Patient Care ❯ Treatment Efficacy

Adverse Effects

NEJM Publication Confirms Phase 3 Win for Brepocitinib in Dermatomyositis

The FDA is conducting a Priority Review with a decision expected in the third quarter of 2026.

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort